发布求助
文献互助 智能选刊 最新文献

Clinical Lipidology最新文献

筛选
英文 中文
Role of lipids and lipoproteins in myocardial biology and in the development of heart failure 脂质和脂蛋白在心肌生物学和心力衰竭发展中的作用
Clinical Lipidology Pub Date : 2015-08-01 DOI: 10.2217/clp.15.20
I. Muthuramu, Neha Singh, Ruhul Amin, B. Geest
{"title":"Role of lipids and lipoproteins in myocardial biology and in the development of heart failure","authors":"I. Muthuramu, Neha Singh, Ruhul Amin, B. Geest","doi":"10.2217/clp.15.20","DOIUrl":"https://doi.org/10.2217/clp.15.20","url":null,"abstract":"Abstract As the population ages, heart failure will continue to be a growing public health problem. Metabolic homeostasis in the heart requires a fine-tuning of metabolism of different substrates. Notwithstanding a retro control of fatty acid and glucose utilization, the heart functions best when it oxidizes both substrates simultaneously. Mismatch between the uptake and oxidation of long-chain fatty acids in the myocardium induces lipotoxicity characterized by the accumulation of triglycerides, diacylglycerols, ceramides and other lipids. Lipotoxicity may result in cardiomyocyte apoptosis, interstitial fibrosis and cardiac dysfunction, and may promote insulin resistance. In this review, we will highlight the impact of lipids and lipoproteins on myocardial biology and on the development of heart failure independent of their effects on coronary heart disease.","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"101 1","pages":"329 - 342"},"PeriodicalIF":0.0,"publicationDate":"2015-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80803047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
The role of LDL-bound apoJ in the development of atherosclerosis 低密度脂蛋白结合apoJ在动脉粥样硬化发生中的作用
Clinical Lipidology Pub Date : 2015-08-01 DOI: 10.2217/clp.15.21
A. Rull, J. Ordóñez‐Llanos, J. L. Sánchez-Quesada
{"title":"The role of LDL-bound apoJ in the development of atherosclerosis","authors":"A. Rull, J. Ordóñez‐Llanos, J. L. Sánchez-Quesada","doi":"10.2217/clp.15.21","DOIUrl":"https://doi.org/10.2217/clp.15.21","url":null,"abstract":"Abstract Aggregation of LDL is considered the initial key event in atherogenesis and apoJ is an extracellular chaperone part of the quality control system against protein aggregation. A minor fraction of apoJ in blood is transported by LDL, but its role is poorly understood. Considering both the importance of LDL aggregation in atherosclerosis and the modulatory role of apoJ on protein aggregation, the function of apoJ bound to LDL could be relevant. Recent studies have shown that apoJ prevents the LDL aggregation and inhibits the cytotoxic potential of modified LDL. Other studies have reported increased content of apoJ in atherogenic LDL fractions. These observations point to apoJ as a key modulator of LDL atherogenicity.","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"61 1","pages":"321 - 328"},"PeriodicalIF":0.0,"publicationDate":"2015-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90702595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Management of lipoprotein X and its complications in a patient with primary sclerosing cholangitis. 原发性硬化性胆管炎患者脂蛋白X及其并发症的处理。
Clinical Lipidology Pub Date : 2015-08-01 DOI: 10.2217/clp.15.23
Eric J Brandt, Shane M Regnier, Edward Ky Leung, Sharon H Chou, Beverly W Baron, Helen S Te, Michael H Davidson, Robert M Sargis
{"title":"Management of lipoprotein X and its complications in a patient with primary sclerosing cholangitis.","authors":"Eric J Brandt,&nbsp;Shane M Regnier,&nbsp;Edward Ky Leung,&nbsp;Sharon H Chou,&nbsp;Beverly W Baron,&nbsp;Helen S Te,&nbsp;Michael H Davidson,&nbsp;Robert M Sargis","doi":"10.2217/clp.15.23","DOIUrl":"https://doi.org/10.2217/clp.15.23","url":null,"abstract":"<p><p>Lipoprotein X (LpX) is an abnormal lipoprotein found in conditions such as lecithin:cholesterol acyltransferase deficiency and cholestatic states (e.g., primary biliary cirrhosis and primary sclerosing cholangitis). Management of severe hypercholesterolemia due to LpX with drugs and physical removal methods is not well established in the literature. A case is discussed of a 51-year-old woman who presented with multiple electrolyte abnormalities, xanthomas and neuropathy found to be secondary to LpX in the setting of primary sclerosing cholangitis. This case highlights that oral medications, including statins, may be insufficient to normalize lipid levels or improve clinical symptoms of LpX and presents therapeutic plasma exchange as a safe and effective therapeutic option to treat the morbid sequela of LpX hyperlipidemia.</p>","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"10 4","pages":"305-312"},"PeriodicalIF":0.0,"publicationDate":"2015-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/clp.15.23","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34109431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 16
Cardiovascular risk in pediatric nonalcoholic fatty liver disease: recent advances 儿童非酒精性脂肪肝的心血管风险:最新进展
Clinical Lipidology Pub Date : 2015-08-01 DOI: 10.2217/clp.15.26
S. Baskar, S. Jhaveri, N. Alkhouri
{"title":"Cardiovascular risk in pediatric nonalcoholic fatty liver disease: recent advances","authors":"S. Baskar, S. Jhaveri, N. Alkhouri","doi":"10.2217/clp.15.26","DOIUrl":"https://doi.org/10.2217/clp.15.26","url":null,"abstract":"Abstract Nonalcoholic fatty liver disease (NAFLD) is the most common form of pediatric chronic liver disease in developed countries. NAFLD has risen to epidemic proportions paralleling that of childhood obesity. It is becoming increasingly evident that NAFLD is strongly linked with cardiovascular disease (CVD), which is the leading cause of mortality in the adult NAFLD population. It is very important for physicians caring for children being cognizant of the potential role of childhood NAFLD as an independent risk factor for CVD. Childhood is a time period where subclinical CVD can be detected, giving us the potential ability to halt or reverse the disease process. In this review, we discuss recent evidence linking childhood NAFLD to CVD and potential pathogenic links.","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"140 1","pages":"351 - 362"},"PeriodicalIF":0.0,"publicationDate":"2015-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80014426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
The potential of apolipoprotein mimetic peptides in the treatment of atherosclerosis. 载脂蛋白模拟肽在动脉粥样硬化治疗中的潜力。
Clinical Lipidology Pub Date : 2015-06-01 DOI: 10.2217/clp.15.18
Luke J Leman
{"title":"The potential of apolipoprotein mimetic peptides in the treatment of atherosclerosis.","authors":"Luke J Leman","doi":"10.2217/clp.15.18","DOIUrl":"https://doi.org/10.2217/clp.15.18","url":null,"abstract":"Abstract “Despite the widespread use of statins to control LDL cholesterol levels and lessen the burden of cardiovascular disease, atherosclerosis remains a leading cause of death worldwide...”","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"10 3","pages":"215-217"},"PeriodicalIF":0.0,"publicationDate":"2015-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/clp.15.18","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34428408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
A critical appraisal of brown adipose tissue metabolism in humans 人类棕色脂肪组织代谢的关键评估
Clinical Lipidology Pub Date : 2015-06-01 DOI: 10.2217/clp.15.14
D. Blondin, Sébastien M. Labbé, É. Turcotte, F. Haman, D. Richard, A. Carpentier
{"title":"A critical appraisal of brown adipose tissue metabolism in humans","authors":"D. Blondin, Sébastien M. Labbé, É. Turcotte, F. Haman, D. Richard, A. Carpentier","doi":"10.2217/clp.15.14","DOIUrl":"https://doi.org/10.2217/clp.15.14","url":null,"abstract":"Abstract The presence of brown adipose tissue (BAT) in adult humans has been rediscovered through the clinical use of the radioactive glucose analog 18F-fluorodeoxyglucose with PET. This has led to numerous studies demonstrating cold exposure as the major physiological modulator of BAT activity. These reports also suggested that age, gender, BMI and the presence of diabetes are also important modulators of BAT volume and metabolic activity. Although 18F-fluorodeoxyglucose PET has provided important information on BAT glucose metabolism, other techniques are being developed and applied to assess other aspects of BAT metabolism. Here, we summarize the current understanding of the pathophysiological functions of BAT in humans and discuss some of the strengths and limitations of the current investigational techniques.","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"6 1","pages":"259 - 280"},"PeriodicalIF":0.0,"publicationDate":"2015-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73711719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 24
Combined therapy with Xuezhikang and low-dose rosuvastatin provides an effective and safe therapeutic strategy for dyslipidemic patients 血脂康联合小剂量瑞舒伐他汀治疗血脂异常是一种安全有效的治疗策略
Clinical Lipidology Pub Date : 2015-06-01 DOI: 10.2217/clp.15.15
Min Wang, Shuiping Zhao, Ming-yue Tan, F. Huang
{"title":"Combined therapy with Xuezhikang and low-dose rosuvastatin provides an effective and safe therapeutic strategy for dyslipidemic patients","authors":"Min Wang, Shuiping Zhao, Ming-yue Tan, F. Huang","doi":"10.2217/clp.15.15","DOIUrl":"https://doi.org/10.2217/clp.15.15","url":null,"abstract":"Abstract Aims: Double-dose statin regimen achieves merely 6% of decrease in serum LDL cholesterol (LDL-C) levels, whereas the risk of side effects increased largely. Methods: In order to evaluate the lipid lowering effects and safety of combined therapy with Xuezhikang (XZK) and low-dose rosuvastatin, we recruited 30 patients to randomly divide into two groups, and then received combined therapy with XZK at 1.2 g/day and rosuvastatin at 5 mg/day or rosuvastatin at 10 mg/day, respectively. After 8 weeks, the subjects in the two groups cross-changed their treatments for the second period (8 weeks). Results: Compared with rosuvastatin alone, the combined therapy induced a significant decrease in LDL-C, total cholesterol and triglyceride with no serious adverse events, and exerted a slight effect on PCSK9 level. Discussion: The results suggest that combined therapy is a first-line therapeutic strategy for dyslipidemia patients.","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"44 1","pages":"243 - 250"},"PeriodicalIF":0.0,"publicationDate":"2015-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74724162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Afamin is a promising novel marker for metabolic syndrome and related diseases Afamin是一种很有前途的代谢综合征及相关疾病的新标志物
Clinical Lipidology Pub Date : 2015-06-01 DOI: 10.2217/clp.15.9
F. Kronenberg, H. Dieplinger
{"title":"Afamin is a promising novel marker for metabolic syndrome and related diseases","authors":"F. Kronenberg, H. Dieplinger","doi":"10.2217/clp.15.9","DOIUrl":"https://doi.org/10.2217/clp.15.9","url":null,"abstract":"Abstract “...recent data from transgenic mice and large human epidemiological studies have revealed a strong association between afamin and the prevalence and development of metabolic syndrome and related diseases.”","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"PP 1","pages":"207 - 210"},"PeriodicalIF":0.0,"publicationDate":"2015-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84534084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Biohumoral and comorbidity determinants of low HDL-C during acute phase response in a setting of in-hospital patients 住院患者急性期低HDL-C的生物体液和合并症决定因素
Clinical Lipidology Pub Date : 2015-06-01 DOI: 10.2217/clp.15.17
S. Vuono, M. Ricci, A. Villa, A. Gentili, M. Scavizzi, G. Ciuffetti, M. Pirro, C. Ferri, G. Lupattelli
{"title":"Biohumoral and comorbidity determinants of low HDL-C during acute phase response in a setting of in-hospital patients","authors":"S. Vuono, M. Ricci, A. Villa, A. Gentili, M. Scavizzi, G. Ciuffetti, M. Pirro, C. Ferri, G. Lupattelli","doi":"10.2217/clp.15.17","DOIUrl":"https://doi.org/10.2217/clp.15.17","url":null,"abstract":"Abstract Aim: To evaluate, in a large population, differences in HDL levels between subjects with acute phase reaction (APR) and subjects without different HDL decreases depending on disease causing APR and correlations between HDL and APR parameters. Materials & methods: In 902 patients we retrospectively evaluated alpha-2-globulins, white blood cells, C-reactive protein (CRP) and lipid profiles. APR was defined by CRP >1.5 mg/dl. Patients were reselected in seven subsets: infections, rheumatic diseases, neoplasms, cerebro-cardiovascular diseases, traumatic/mental disorders, endocrine/metabolic diseases and controls. Results: Subjects with APR showed significantly lower HDL-C (age and gender adjusted). Subset ‘infections’ showed the lowest HDL-C values and the highest CRP values. HDL-C had inverse significant correlation with all APR parameters. At stepwise regression analysis gender, albumin, TG and CRP were independent predictors of HDL-C. Conclusion: Our data produced the observation that subjects with APR show HDL-C levels lower than non-APR subjects to a large and heterogeneous population. HDL-C levels decrease in a different manner on the basis of the disease causing APR, maybe depending on inflammation intensity.","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"95 1","pages":"227 - 233"},"PeriodicalIF":0.0,"publicationDate":"2015-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79624743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The National Lipid Association Annual Summary of Clinical Lipidology 2015: one-stop shopping for the information age 全国脂质协会2015年度临床脂质学总结:信息时代的一站式购物
Clinical Lipidology Pub Date : 2015-06-01 DOI: 10.2217/CLP.15.11
H. Bays
{"title":"The National Lipid Association Annual Summary of Clinical Lipidology 2015: one-stop shopping for the information age","authors":"H. Bays","doi":"10.2217/CLP.15.11","DOIUrl":"https://doi.org/10.2217/CLP.15.11","url":null,"abstract":"Abstract “...the 2015 NLA Annual Summary of Clinical Lipidology is the first edition, with yearly updates planned for this ‘living document,’ thus reflecting the latest developments in lipidology.”","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"98 1","pages":"211 - 213"},"PeriodicalIF":0.0,"publicationDate":"2015-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89264561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信